Cell targeting by the staphylococcus aureus pore-forming toxins: It's not just about lipids

Trends in Microbiology

Volumn 22, Issue 1, 2014, Pages 21-27

  DuMont, Ashley L ^a   Torres, Victor J ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Membrane proteins; Pore forming toxins; Staphylococcus aureus; Toxin receptors

Indexed keywords

ADAM10 ENDOPEPTIDASE; BACTERIAL PROTEIN; CELL RECEPTOR; CHEMOKINE RECEPTOR CCR5; COMPLEMENT COMPONENT C5A RECEPTOR; INTERMEDILYSIN; MEMBRANE LIPID; PANTON VALENTINE LEUKOCIDIN; PORE FORMING TOXIN; STAPHYLOCOCCUS TOXIN; UNCLASSIFIED DRUG;

BACTERIAL VIRULENCE; BINDING AFFINITY; CELL TYPE; HOST PATHOGEN INTERACTION; HUMAN; LIPID BILAYER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN PROTEIN INTERACTION; REVIEW; SPECIES DIFFERENCE; STAPHYLOCOCCUS INFECTION; TOXIN ANALYSIS; TOXIN STRUCTURE; TROPISM;

ANIMALIA; STAPHYLOCOCCUS AUREUS;

MEMBRANE PROTEINS; PORE-FORMING TOXINS; STAPHYLOCOCCUS AUREUS; TOXIN RECEPTORS;

ANIMALS; BACTERIAL TOXINS; DISEASE MODELS, ANIMAL; HUMANS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VIRULENCE; VIRULENCE FACTORS;

EID: 84891372554     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2013.10.004     Document Type: Review

References (77)

1. Alonzo F., Torres V.J. Bacterial survival amidst an immune onslaught: the contribution of the Staphylococcus aureus leukotoxins. PLoS Pathog. 2013, 9:e1003143.
2. Young J.A., Collier R.J. Anthrax toxin: receptor binding, internalization, pore formation, and translocation. Annu. Rev. Biochem. 2007, 76:243-265.
3. Birmingham C.L., et al. Listeriolysin O allows Listeria monocytogenes replication in macrophage vacuoles. Nature 2008, 451:350-354.
4. Vadia S., et al. The pore-forming toxin listeriolysin O mediates a novel entry pathway of L. monocytogenes into human hepatocytes. PLoS Pathog. 2011, 7:e1002356.
5. Vandenesch F., et al. Staphylococcus aureus hemolysins, bi-component leukocidins, and cytolytic peptides: a redundant arsenal of membrane-damaging virulence factors?. Front. Cell. Infect. Microbiol. 2012, 2:12.
6. Lowy F.D. Staphylococcus aureus infections. N. Engl. J. Med. 1998, 339:520-532.
7. Deleo F.R., et al. Community-associated meticillin-resistant Staphylococcus aureus. Lancet 2010, 375:1557-1568.
8. Gilbert R.J. Cholesterol-dependent cytolysins. Adv. Exp. Med. Biol. 2010, 677:56-66.
9. Soltani C.E., et al. Structural elements of the cholesterol-dependent cytolysins that are responsible for their cholesterol-sensitive membrane interactions. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:20226-20231.
10. Diep D.B., et al. Glycosylphosphatidylinositol anchors of membrane glycoproteins are binding determinants for the channel-forming toxin aerolysin. J. Biol. Chem. 1998, 273:2355-2360.
11. Hong Y., et al. Requirement of N-glycan on GPI-anchored proteins for efficient binding of aerolysin but not Clostridium septicum alpha-toxin. EMBO J. 2002, 21:5047-5056.
12. Nelson K.L., et al. The glycosylphosphatidylinositol-anchored surface glycoprotein Thy-1 is a receptor for the channel-forming toxin aerolysin. J. Biol. Chem. 1997, 272:12170-12174.
13. MacKenzie C.R., et al. Analysis of receptor binding by the channel-forming toxin aerolysin using surface plasmon resonance. J. Biol. Chem. 1999, 274:22604-22609.
14. Cowell S., et al. The erythrocyte receptor for the channel-forming toxin aerolysin is a novel glycosylphosphatidylinositol-anchored protein. Mol. Microbiol. 1997, 25:343-350.
15. Elliott J.L., et al. A quantitative study of the interactions of Bacillus anthracis edema factor and lethal factor with activated protective antigen. Biochemistry 2000, 39:6706-6713.
16. Milne J.C., et al. Anthrax protective antigen forms oligomers during intoxication of mammalian cells. J. Biol. Chem. 1994, 269:20607-20612.
17. Bradley K.A., et al. Identification of the cellular receptor for anthrax toxin. Nature 2001, 414:225-229.
18. Scobie H.M., et al. Human capillary morphogenesis protein 2 functions as an anthrax toxin receptor. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:5170-5174.
19. Dickeson S.K., Santoro S.A. Ligand recognition by the I domain-containing integrins. Cell. Mol. Life Sci. 1998, 54:556-566.
20. Martchenko M., et al. Heterodimeric integrin complexes containing beta1-integrin promote internalization and lethality of anthrax toxin. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15583-15588.
21. Nagamune H., et al. Intermedilysin, a novel cytotoxin specific for human cells secreted by Streptococcus intermedius UNS46 isolated from a human liver abscess. Infect. Immun. 1996, 64:3093-3100.
22. Giddings K.S., et al. Human CD59 is a receptor for the cholesterol-dependent cytolysin intermedilysin. Nat. Struct. Mol. Biol. 2004, 11:1173-1178.
23. Rollins S.A., Sims P.J. The complement-inhibitory activity of CD59 resides in its capacity to block incorporation of C9 into membrane C5b-9. J. Immunol. 1990, 144:3478-3483.
24. Menestrina G., et al. Mode of action of beta-barrel pore-forming toxins of the staphylococcal alpha-hemolysin family. Toxicon 2001, 39:1661-1672.
25. Yamashita K., et al. Crystal structure of the octameric pore of staphylococcal gamma-hemolysin reveals the beta-barrel pore formation mechanism by two components. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:17314-17319.
26. Song L., et al. Structure of staphylococcal alpha-hemolysin, a heptameric transmembrane pore. Science 1996, 274:1859-1866.
27. Berube B.J., Bubeck Wardenburg J. Staphylococcus aureus alpha-toxin: nearly a century of intrigue. Toxins 2013, 5:1140-1166.
28. Woodin A.M. Purification of the two components of leucocidin from Staphylococcus aureus. Biochem. J. 1960, 75:158-165.
29. von Eiff C., et al. Prevalence of genes encoding for members of the staphylococcal leukotoxin family among clinical isolates of Staphylococcus aureus. Diagn. Microbiol. Infect. Dis. 2004, 49:157-162.
30. Morinaga N., et al. Purification, cloning and characterization of variant LukE-LukD with strong leukocidal activity of staphylococcal bi-component leukotoxin family. Microbiol. Immunol. 2003, 47:81-90.
31. McCarthy A.J., Lindsay J.A. Staphylococcus aureus innate immune evasion is lineage-specific: a bioinfomatics study. Infect. Genet. Evol. 2013, 19C:7-14.
32. Naimi T.S., et al. Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection. JAMA 2003, 290:2976-2984.
33. Lina G., et al. Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia. Clin. Infect. Dis. 1999, 29:1128-1132.
34. Rainard P., et al. Leucotoxic activities of Staphylococcus aureus strains isolated from cows, ewes, and goats with mastitis: importance of LukM/LukF'-PV leukotoxin. Clin. Diagn. Lab. Immunol. 2003, 10:272-277.
35. Prevost G., et al. Characterisation of a synergohymenotropic toxin produced by Staphylococcus intermedius. FEBS Lett. 1995, 376:135-140.
36. Aman M.J., et al. Structural model of the pre-pore ring-like structure of Panton-Valentine leukocidin: providing dimensionality to biophysical and mutational data. J. Biomol. Struct. Dyn. 2010, 28:1-12.
37. Jayasinghe L., Bayley H. The leukocidin pore: evidence for an octamer with four LukF subunits and four LukS subunits alternating around a central axis. Protein Sci. 2005, 14:2550-2561.
38. Miles G., et al. Subunit composition of a bicomponent toxin: staphylococcal leukocidin forms an octameric transmembrane pore. Protein Sci. 2002, 11:894-902.
39. Colin D.A., et al. Interaction of the two components of leukocidin from Staphylococcus aureus with human polymorphonuclear leukocyte membranes: sequential binding and subsequent activation. Infect. Immun. 1994, 62:3184-3188.
40. Noda M., et al. Fixation and inactivation of staphylococcal leukocidin by phosphatidylcholine and ganglioside GM1 in rabbit polymorphonuclear leukocytes. Infect. Immun. 1980, 29:678-684.
41. Valeva A., et al. Evidence that clustered phosphocholine head groups serve as sites for binding and assembly of an oligomeric protein pore. J. Biol. Chem. 2006, 281:26014-26021.
42. Cassidy P.S., Harshman S. The binding of staphylococcal 125I-alpha-toxin (B) to erythrocytes. J. Biol. Chem. 1973, 248:5545-5546.
43. Cassidy P., Harshman S. Studies on the binding of staphylococcal 125I-labeled alpha-toxin to rabbit erythrocytes. Biochemistry 1976, 15:2348-2355.
44. Bhakdi S., et al. Release of interleukin-1 beta associated with potent cytocidal action of staphylococcal alpha-toxin on human monocytes. Infect. Immun. 1989, 57:3512-3519.
45. Valeva A., et al. Transmembrane beta-barrel of staphylococcal alpha-toxin forms in sensitive but not in resistant cells. Proc. Natl. Acad. Sci. U.S.A. 1997, 94:11607-11611.
46. Loffler B., et al. Staphylococcus aureus Panton-Valentine leukocidin is a very potent cytotoxic factor for human neutrophils. PLoS Pathog. 2010, 6:e1000715.
47. Malachowa N., et al. Staphylococcus aureus leukotoxin GH promotes inflammation. J. Infect. Dis. 2012, 206:1185-1193.
48. Alonzo F., et al. Staphylococcus aureus leucocidin ED contributes to systemic infection by targeting neutrophils and promoting bacterial growth in vivo. Mol. Microbiol. 2012, 83:423-435.
49. Alonzo F., et al. CCR5 is a receptor for Staphylococcus aureus leukotoxin ED. Nature 2013, 493:51-55.
50. Wilke G.A., Bubeck Wardenburg J. Role of a disintegrin and metalloprotease 10 in Staphylococcus aureus alpha-hemolysin-mediated cellular injury. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:13473-13478.
51. Reiss K., Saftig P. The "a disintegrin and metalloprotease" (ADAM) family of sheddases: physiological and cellular functions. Semin. Cell Dev. Biol. 2009, 20:126-137.
52. White J.M. ADAMs: modulators of cell-cell and cell-matrix interactions. Curr. Opin. Cell Biol. 2003, 15:598-606.
53. Deng H., et al. Identification of a major co-receptor for primary isolates of HIV-1. Nature 1996, 381:661-666.
54. Doranz B.J., et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996, 85:1149-1158.
55. Blanpain C., et al. CCR5 binds multiple CC-chemokines: MCP-3 acts as a natural antagonist. Blood 1999, 94:1899-1905.
56. Spaan A.N., et al. The staphylococcal toxin Panton-Valentine leukocidin targets human c5a receptors. Cell Host Microbe 2013, 13:584-594.
57. Yoong P., Torres V.J. The effects of Staphylococcus aureus leukotoxins on the host: cell lysis and beyond. Curr. Opin. Microbiol. 2013, 16:63-69.
58. Gauduchon V., et al. Flow cytometric determination of Panton-Valentine leucocidin S component binding. Infect. Immun. 2001, 69:2390-2395.
59. DuMont A.L., et al. Characterization of a new cytotoxin that contributes to Staphylococcus aureus pathogenesis. Mol. Microbiol. 2011, 79:814-825.
60. Dumont A.L., et al. Staphylococcus aureus LukAB cytotoxin kills human neutrophils by targeting the CD11b subunit of the integrin Mac-1. Proc. Natl. Acad. Sci. U.S.A. 2013, 110:10794-10799.
61. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
62. Solovjov D.A., et al. Distinct roles for the alpha and beta subunits in the functions of integrin alphaMbeta2. J. Biol. Chem. 2005, 280:1336-1345.
63. Ho M.K., Springer T.A. Mac-1 antigen: quantitative expression in macrophage populations and tissues, and immunofluorescent localization in spleen. J. Immunol. 1982, 128:2281-2286.
64. Bubeck Wardenburg J., et al. Panton-Valentine leukocidin is not a virulence determinant in murine models of community-associated methicillin-resistant Staphylococcus aureus disease. J. Infect. Dis. 2008, 198:1166-1170.
65. Kennedy A.D., et al. Targeting of alpha-hemolysin by active or passive immunization decreases severity of USA300 skin infection in a mouse model. J. Infect. Dis. 2010, 202:1050-1058.
66. Inoshima I., et al. A Staphylococcus aureus pore-forming toxin subverts the activity of ADAM10 to cause lethal infection in mice. Nat. Med. 2011, 17:1310-1314.
67. Powers M.E., et al. ADAM10 mediates vascular injury induced by Staphylococcus aureus alpha-hemolysin. J. Infect. Dis. 2012, 206:352-356.
68. Inoshima N., et al. Genetic requirement for ADAM10 in severe Staphylococcus aureus skin infection. J. Invest. Dermatol. 2012, 132:1513-1516.
69. Gillet Y., et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet 2002, 359:753-759.
70. Voyich J.M., et al. Is Panton-Valentine leukocidin the major virulence determinant in community-associated methicillin-resistant Staphylococcus aureus disease?. J. Infect. Dis. 2006, 194:1761-1770.
71. Labandeira-Rey M., et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science 2007, 315:1130-1133.
72. Lipinska U., et al. Panton-Valentine leukocidin does play a role in the early stage of Staphylococcus aureus skin infections: a rabbit model. PLoS ONE 2011, 6:e22864.
73. Kobayashi S.D., et al. Comparative analysis of USA300 virulence determinants in a rabbit model of skin and soft tissue infection. J. Infect. Dis. 2011, 204:937-941.
74. Zivkovic A., et al. TLR 2 and CD14 mediate innate immunity and lung inflammation to staphylococcal Panton-Valentine leukocidin in vivo. J. Immunol. 2011, 186:1608-1617.
75. DuMont A.L., et al. Staphylococcus aureus elaborates leukocidin AB to mediate escape from within human neutrophils. Infect. Immun. 2013, 81:1830-1841.
76. Ventura C.L., et al. Identification of a novel Staphylococcus aureus two-component leukotoxin using cell surface proteomics. PLoS ONE 2010, 5:e11634.
77. Diep B.A., et al. Polymorphonuclear leukocytes mediate Staphylococcus aureus Panton-Valentine leukocidin-induced lung inflammation and injury. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:5587-5592.